May 8, 2020 / 6:29 PM / 23 days ago

BRIEF-Eli Lilly Says Higher Investigational Doses Of Trulicity (Dulaglutide) Meaningfully Reduced A1C And Body Weight In People With Type 2 Diabetes

May 8 (Reuters) - Eli Lilly and Co:

* HIGHER INVESTIGATIONAL DOSES OF TRULICITY® (DULAGLUTIDE) MEANINGFULLY REDUCED A1C AND BODY WEIGHT IN PEOPLE WITH TYPE 2 DIABETES

* ELI LILLY AND CO - SAFETY & TOLERABILITY PROFILE OF INVESTIGATIONAL DULAGLUTIDE DOSES WAS CONSISTENT WITH KNOWN PROFILE OF TRULICITY 1.5 MG

* ELI LILLY AND CO - AWARD-11 RESULTS HAVE BEEN SUBMITTED TO REGULATORY AUTHORITIES IN U.S. AND EUROPE FOR REVIEW Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below